WINT – windtree therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia [Yahoo! Finance]
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction [Yahoo! Finance]
Windtree Therapeutics, Inc. (NASDAQ: WINT) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Form 8-K WINDTREE THERAPEUTICS For: Dec 02
Form 8-K WINDTREE THERAPEUTICS For: Dec 04
Form 8-K WINDTREE THERAPEUTICS For: Nov 21
Form 10-Q WINDTREE THERAPEUTICS For: Sep 30
Form 8-K/A WINDTREE THERAPEUTICS For: Sep 25
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.